These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22107797)

  • 1. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro.
    Satishkumar R; Vertegel AA
    Nanotechnology; 2011 Dec; 22(50):505103. PubMed ID: 22107797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLGA nanoparticle-encapsulated lysostaphin for the treatment of Staphylococcus aureus infections.
    Landa G; Aguerri L; Irusta S; Mendoza G; Arruebo M
    Int J Biol Macromol; 2024 Jun; 271(Pt 1):132563. PubMed ID: 38782313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internally quenched peptides for the study of lysostaphin: An antimicrobial protease that kills Staphylococcus aureus.
    Warfield R; Bardelang P; Saunders H; Chan WC; Penfold C; James R; Thomas NR
    Org Biomol Chem; 2006 Oct; 4(19):3626-38. PubMed ID: 16990938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin.
    Graham S; Coote PJ
    J Antimicrob Chemother; 2007 Apr; 59(4):759-62. PubMed ID: 17324959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial and antibiofilm surfaces through polydopamine-assisted immobilization of lysostaphin as an antibacterial enzyme.
    Yeroslavsky G; Girshevitz O; Foster-Frey J; Donovan DM; Rahimipour S
    Langmuir; 2015 Jan; 31(3):1064-73. PubMed ID: 25547537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
    Kusuma CM; Kokai-Kun JF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysostaphin-coated catheters eradicate Staphylococccus aureus challenge and block surface colonization.
    Shah A; Mond J; Walsh S
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2704-7. PubMed ID: 15215130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of Polycations on Antibacterial Activity of Lysostaphin].
    Kulikov SN; Khairullin RZ; Varlamov VP
    Prikl Biokhim Mikrobiol; 2015; 51(6):610-5. PubMed ID: 26859963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the antimicrobial activity of lysostaphin-coated hernia repair meshes.
    Satishkumar R; Sankar S; Yurko Y; Lincourt A; Shipp J; Heniford BT; Vertegel A
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4379-85. PubMed ID: 21709102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA.
    Becker SC; Foster-Frey J; Donovan DM
    FEMS Microbiol Lett; 2008 Oct; 287(2):185-91. PubMed ID: 18721148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysostaphin: an antistaphylococcal agent.
    Kumar JK
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immobilization of recombinant lysostaphin on nanoparticle through biotin-streptavidin conjugation technology as a geometrical progressed confrontation against Staphylococcus aureus infection.
    Ehsani G; Farahnak M; Norouzian D; Ehsani P
    Biotechnol Appl Biochem; 2021 Oct; 68(5):1058-1066. PubMed ID: 32918836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37.
    Sadeghi S; Bakhshandeh H; Ahangari Cohan R; Peirovi A; Ehsani P; Norouzian D
    Int J Nanomedicine; 2019; 14():9777-9792. PubMed ID: 31849468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEI-coated PLA nanoparticles to enhance the antimicrobial activity of carvacrol.
    Niza E; Božik M; Bravo I; Clemente-Casares P; Lara-Sanchez A; Juan A; Klouček P; Alonso-Moreno C
    Food Chem; 2020 Oct; 328():127131. PubMed ID: 32485586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
    LaPlante KL
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient adsorption of lysostaphin on bacterial cells of lysostaphin-resistant Staphylococcus aureus mutant.
    Sakurada J; Murai M; Zhijun L; Usui A; Seki K; Kobayashi K; Sumi Y; Jitsukawa H; Masuda S
    Microbiol Immunol; 1993; 37(1):29-34. PubMed ID: 8474355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood.
    von Eiff C; Kokai-Kun JF; Becker K; Peters G
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3613-5. PubMed ID: 14576128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct observation of Staphylococcus aureus cell wall digestion by lysostaphin.
    Francius G; Domenech O; Mingeot-Leclercq MP; Dufrêne YF
    J Bacteriol; 2008 Dec; 190(24):7904-9. PubMed ID: 18835985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysostaphin-coated titan-implants preventing localized osteitis by Staphylococcus aureus in a mouse model.
    Windolf CD; Lögters T; Scholz M; Windolf J; Flohé S
    PLoS One; 2014; 9(12):e115940. PubMed ID: 25536060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX; Kong L; Weisman LE
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.